Apr 25 |
Recent 13% pullback isn't enough to hurt long-term Autolus Therapeutics (NASDAQ:AUTL) shareholders, they're still up 157% over 1 year
|
Apr 24 |
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
|
Apr 23 |
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
|
Apr 2 |
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B...
|
Mar 21 |
Q4 2023 BioNTech SE Earnings Call
|
Mar 17 |
Autolus Therapeutics plc (NASDAQ:AUTL) Q4 2023 Earnings Call Transcript
|
Mar 15 |
Autolus Therapeutics Full Year 2023 Earnings: EPS Misses Expectations
|
Mar 15 |
Q4 2023 Autolus Therapeutics PLC Earnings Call
|
Mar 15 |
Autolus Therapeutics plc (AUTL) Q4 2023 Earnings Call Transcript
|
Mar 14 |
Autolus Therapeutics PLC Reports Full Year 2023 Financial Results
|